Corcept Therapeutics Inc (CORT)
50.07
+2.45
(+5.14%)
USD |
NASDAQ |
Nov 04, 16:00
50.07
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Price to Book Value: 8.212 for Nov. 4, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 7.810 |
| October 31, 2024 | 8.032 |
| October 30, 2024 | 7.690 |
| October 29, 2024 | 7.907 |
| October 28, 2024 | 7.928 |
| October 25, 2024 | 7.754 |
| October 24, 2024 | 7.748 |
| October 23, 2024 | 7.882 |
| October 22, 2024 | 8.018 |
| October 21, 2024 | 8.049 |
| October 18, 2024 | 8.154 |
| October 17, 2024 | 7.731 |
| October 16, 2024 | 7.747 |
| October 15, 2024 | 7.677 |
| October 14, 2024 | 7.424 |
| October 11, 2024 | 7.446 |
| October 10, 2024 | 7.416 |
| October 09, 2024 | 7.529 |
| October 08, 2024 | 7.503 |
| October 07, 2024 | 7.320 |
| October 04, 2024 | 7.446 |
| October 03, 2024 | 7.382 |
| October 02, 2024 | 7.516 |
| October 01, 2024 | 7.662 |
| September 30, 2024 | 7.585 |
| Date | Value |
|---|---|
| September 27, 2024 | 7.699 |
| September 26, 2024 | 7.585 |
| September 25, 2024 | 7.455 |
| September 24, 2024 | 7.711 |
| September 23, 2024 | 7.527 |
| September 20, 2024 | 7.404 |
| September 19, 2024 | 7.171 |
| September 18, 2024 | 7.408 |
| September 17, 2024 | 6.959 |
| September 16, 2024 | 6.742 |
| September 13, 2024 | 6.679 |
| September 12, 2024 | 6.258 |
| September 11, 2024 | 6.230 |
| September 10, 2024 | 6.139 |
| September 09, 2024 | 6.081 |
| September 06, 2024 | 6.025 |
| September 05, 2024 | 5.976 |
| September 04, 2024 | 6.067 |
| September 03, 2024 | 6.004 |
| August 30, 2024 | 6.186 |
| August 29, 2024 | 6.158 |
| August 28, 2024 | 6.036 |
| August 27, 2024 | 6.074 |
| August 26, 2024 | 6.134 |
| August 23, 2024 | 6.097 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
3.078
Minimum
Apr 07 2020
8.221
Maximum
Sep 14 2023
5.255
Average
5.023
Median
Price to Book Value Benchmarks
| ADMA Biologics Inc | 23.68 |
| Akebia Therapeutics Inc | -- |
| Bioventus Inc | 5.920 |
| Alnylam Pharmaceuticals Inc | 1076.61 |
| Catalyst Pharmaceuticals Inc | 4.240 |
Price to Book Value Related Metrics
| PE Ratio | 39.74 |
| PS Ratio | 8.876 |
| PEG Ratio | 0.7153 |
| Price to Free Cash Flow | 39.12 |
| Price | 50.07 |
| Earnings Yield | 2.52% |
| Market Cap | 5.246B |
| PEGY Ratio | 0.7153 |
| Operating PE Ratio | 38.92 |
| Normalized PE Ratio | 39.74 |